Table 4 Comparison of adverse events of MMF and CYC therapy
Parameter | CYC (N = 21) | MMF (N = 21) | P value | Odds ratio | 95% Confidence interval |
|---|---|---|---|---|---|
Alopecia | 16 (76.2%) | 0 (0.00%) | <.001 | n/a | n/a |
Nausea/Vomiting | 16 (76.2%) | 0 (0.0%) | <.001 | n/a | n/a |
Headache | 8 (38.09%) | 4 (19.04%) | 0.778 | 0.423 | 0.084–3.456 |
Backache | 6 (28.57%) | 4 (19.04%) | 0.887 | 0.632 | 0.094–4.230 |
Urinary tract infection | 4 (19.04%) | 2 (9.52%) | 0.796 | 0.473 | 0.083–3.492 |
Herpes Zoster | 3 (14.3%) | 3 (14.3%) | 0.337 | 1.000 | 0.178–5.632 |
Chest Infection | 3 (14.3%) | 2 (9.5%) | 0.328 | 0.632 | 0.094–4.230 |